Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T21:56:34.733Z.
Calculation as of: 2026-10-06T21:56:34.733Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f97479f440d7a03605f533a56e26179237db48e588053495707f458dff3bcd44
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$5.06B
Price/FCF Ratio
20.56
TTM Avg
18.20
3Y Avg
218.90
5Y Avg
218.90
Market Cap
$5.07B
Price/FCF Ratio
24.93
TTM Avg
26.02
3Y Avg
39.55
5Y Avg
43.37
Market Cap
$5.09B
Price/FCF Ratio
N/A
TTM Avg
35.18
3Y Avg
35.18
5Y Avg
35.18
Market Cap
$4.83B
Price/FCF Ratio
N/A
TTM Avg
99.02
3Y Avg
99.02
5Y Avg
99.02
Market Cap
$4.78B
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Erasca, Inc. (ERAS) | $4.96B | N/A | N/A | N/A | N/A |
| Waystar Holding Corp. (WAY)vs › | $5.06B | 20.56 | 18.20 | 218.90 | 218.90 |
| Merit Medical Systems, Inc. (MMSI)vs › | $5.07B | 24.93 | 26.02 | 39.55 | 43.37 |
| Scholar Rock Holding Corporation (SRRK)vs › | $5.09B | N/A | 35.18 | 35.18 | 35.18 |
| Oruka Therapeutics, Inc. (ORKA)vs › | $4.84B | N/A | N/A | N/A | N/A |
| Mirum Pharmaceuticals, Inc. (MIRM)vs › | $4.83B | N/A | 99.02 | 99.02 | 99.02 |
| Dianthus Therapeutics, Inc. (DNTH)vs › | $4.78B | N/A | N/A | N/A | N/A |
| Cogent Biosciences, Inc. (COGT)vs › | $5.19B | N/A | N/A | N/A | N/A |
| Doximity, Inc. (DOCS)vs › | $5.20B | 17.37 | 21.46 | 35.27 | 47.07 |
| Definium Therapeutics, Inc. (DFTX)vs › | $4.73B | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
